Prevalence, aetiology and associated co-morbidities of elevated aminotransferases in a German cohort of orthopaedic surgery patients

Zeitschrift fur Gastroenterologie

Volumn 46, Issue 5, 2008, Pages 415-420

  Lobstein, S ^a   Kaiser, T ^a   Liebert, U ^a   Wojan, M ^a   Leichtle, A ^a   Mossner J ^a   Wiegand, J ^a   Tillmann, Hans L ^a,b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Aetiology; Comorbidities; Elevated aminotransferases; Prevalence

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; FEMALE; GERMANY; HEPATITIS B; HEPATITIS C; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOPEDIC SURGERY; PREVALENCE;

ADULT; AGED; ALANINE TRANSAMINASE; ALCOHOL DRINKING; ASPARTATE AMINOTRANSFERASES; BODY MASS INDEX; COHORT STUDIES; COMORBIDITY; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GERMANY; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; HYPERURICEMIA; LIVER FUNCTION TESTS; MALE; MASS SCREENING; MIDDLE AGED; MYOCARDIAL ISCHEMIA; ORTHOPEDIC PROCEDURES; REFERENCE VALUES;

EID: 47649112581     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1027157     Document Type: Article

References (19)

1. Wiegand J, Kaiser T, Lobstein S et al. Low prevalence of chronic hepatitis C, but high prevalence of elevated aminotransferases in a cohort of 2026 patients referred for orthopaedic surgery in the Eastern part of Germany. Z Gastroenterol 2006; 44: 11-14
2. Ioannou GN, Boyko EJ, Lee SP. The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2002. Am J Gastroenterol 2006; 101: 76-82
3. Papatheodoridis GV, Goulis J, Christodoulou D. High prevalence of elevated liver enzymes in blood donors: associations with male gender and central obesity. Eur J Gastroenterol Hepatol 2007; 19: 281-287
4. Wannamethee SG, Shaper AG, Lennon L et al. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care 2005; 28: 2913-2918
5. Sattar N, Scherbakova O, Ford I. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes 2004; 53: 2855-2860
6. Kim HC, Choi KS, Jang YH et al. Normal serum aminotransferase and the metabolic syndrome: Korean National Health and Nutrition Examination Surveys. Yonsei Medical J 2006; 47: 542-550
7. Narjes H, Nehmiz G. Effect of hospitalisation on liver enzymes in healthy subjects. Eur J Clin Pharmacol 2000; 56: 329-333
8. Rosenzweig P, Miget N, Brohier S. Transaminase elevation on placebo during phase I trials: prevalence and significance. Br J Clin Pharmacol 1999; 48: 19-23
9. Kim HC, Nam CM, Jee SH et al. Normal serum aminotransferase concentration and risk of mortality from liver disease: prospective cohort study. BMJ 2004; 328: 983
10. Whitehead TP, Robinson D, Allaway SL. The effects of cigarette smoking and alcohol consumption on serum liver enzyme activities: a dose-related study in men. Ann Clin Biochem 1996; 33 (Pt 6): 530-535
11. Browning JD, Szczepaniak LS, Dobbins R et al. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology 2004; 40: 1387-1395
12. Chen CH, Huang MH, Yang JC et al. Prevalence and etiology of elevated serum alanine aminotransferase level in an adult population in Taiwan. J Gastroenterol Hepatol 2007; 22: 1482-1489
13. Bedogni G, Migliolo L, Masutti F et al. Prevalence of and risk factors for non-alcoholic fatty liver disease: The Dionysos Nutrition and Liver Study. Hepatology 2005; 42: 44-52
14. Schindhelm RK, Dekker JM, Nijpels G et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 2007; 191: 391-396
15. Adibi P, Sadeghi M, Mahsa M et al. Prediction of coronary atherosclerosic disease with liver transaminase level. Liver International 2007; 27: 895-900
16. Suzuki A, Lindor K, St Save J et al. Effect of changes on body weight and lifestyle in non-alcoholic fatty liver disease. J Hepatol 2005; 43: 1060-1066
17. Abboud G, Kaplowitz N. Drug-induced liver injury. Drug Saf 2007; 30: 277-294
18. Guthrie RM, Martin DR. The safety of rosuvastatin: effects on renal and hepatic function. Expert Opin Drug Saf 2007; 6: 573-581
19. Browning JD. Statins and hepatic steatosis: Perspectives from the Dallas Heart Study. Hepatology 2006; 44: 466-471